{"id":50486,"date":"2022-11-04T04:02:20","date_gmt":"2022-11-04T03:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/"},"modified":"2022-11-04T04:02:20","modified_gmt":"2022-11-04T03:02:20","slug":"sinovac-varicella-vaccine-prequalified-by-who","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/","title":{"rendered":"SINOVAC Varicella Vaccine Prequalified by WHO"},"content":{"rendered":"<div>\n<p>BEIJING&#8211;(BUSINESS WIRE)&#8211;Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/4\/logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/21\/logo.jpg\"><\/a><\/p>\n<p>\nThe varicella vaccine is derived from the Oka strain and propagated in SINOVAC\u2019s proprietary Human Diploid Cell (SV-1 strain), which is made by culturing and harvesting the virus, adding stabilizers and freeze-drying.\n<\/p>\n<p>\nAccording to a phase III efficacy study, the seroconversion rate of the vaccinated children group, ages 1 to 12 years old, was 97.1%; the efficacy of the vaccine was 87.1% against varicella and 89.2% for breakthrough varicella. The vaccine provides 100% protection against moderate and severe cases.\n<\/p>\n<p>\nMr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, \u201cNow that SINOVAC has received WHO prequalification for our varicella vaccine, we can provide a new weapon for prevention and control of infectious diseases globally. In the future, we will continue to work on more clinical trials, registrations and approvals for vaccines worldwide, to offer the world high-quality vaccines and ensure the accessibility and affordability of these public goods.\u201d\n<\/p>\n<p>\nPreviously, three other vaccines by SINOVAC were also approved by WHO in various uses and conditions, including Healive\u00ae (the hepatitis A vaccine), CoronaVac\u00ae (the COVID-19 vaccine) and the Sabin-strain inactivated polio vaccine.\n<\/p>\n<p>\nSINOVAC has been acting on its mission to \u201cSupply Vaccines to Eliminate Human Diseases\u201d. So far, SINOVAC\u2019s vaccines have been distributed to more than 80 countries and regions around the world. The Company offers high-quality and affordable vaccines for global prevention and control of infectious diseases.\n<\/p>\n<p>\n<b>About SINOVAC<\/b>\n<\/p>\n<p>\nSinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&amp;D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.\n<\/p>\n<p>\nSINOVAC\u2019s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, poliomyelitis, etc.\n<\/p>\n<p>\nThe COVID-19 vaccine, CoronaVac\u00ae, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive\u00ae, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive\u00ae, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC\u2019s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.\n<\/p>\n<p>\nSINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1\u00ae, which has supplied the Chinese government&#8217;s vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu\u00ae, to the Chinese government stockpiling program.\n<\/p>\n<p>\nSINOVAC continually dedicates itself to new vaccine R&amp;D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.\n<\/p>\n<p>\nFor more information, please see the Company\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sinovac.com&amp;esheet=52960923&amp;newsitemid=20221103006414&amp;lan=en-US&amp;anchor=www.sinovac.com&amp;index=1&amp;md5=781f6d9b2dcc617c9fe2c27f200788d6\" rel=\"nofollow noopener\" shape=\"rect\">www.sinovac.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nSinovac Biotech Ltd.<br \/>\n<br \/>PR Team<br \/>\n<br \/><a target=\"_blank\" href=\"m&#97;&#105;&#x6c;&#x74;o:&#112;&#114;&#x40;&#x73;in&#111;&#118;&#x61;&#x63;&#46;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">p&#114;&#x40;&#x73;i&#110;&#x6f;&#x76;a&#99;&#46;&#x63;&#x6f;m<\/a>\n<\/p>\n<p>\nIR Team<br \/>\n<br \/>ICR Inc.<br \/>\n<br \/>Bill Zima<br \/>\n<br \/>U.S.: 1-646-308-1707<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;o:&#x77;&#x69;&#x6c;&#x6c;&#105;&#97;m&#46;&#x7a;&#x69;&#x6d;&#97;&#64;&#105;cr&#x69;&#x6e;&#x63;&#46;&#99;om\" rel=\"nofollow noopener\" shape=\"rect\">&#119;&#x69;l&#108;&#x69;a&#109;&#x2e;z&#105;&#x6d;a&#64;&#x69;c&#114;&#x69;n&#99;&#x2e;c&#111;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING&#8211;(BUSINESS WIRE)&#8211;Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50486","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SINOVAC Varicella Vaccine Prequalified by WHO - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SINOVAC Varicella Vaccine Prequalified by WHO - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BEIJING&#8211;(BUSINESS WIRE)&#8211;Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-04T03:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SINOVAC Varicella Vaccine Prequalified by WHO\",\"datePublished\":\"2022-11-04T03:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006414\\\/en\\\/1625794\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/\",\"name\":\"SINOVAC Varicella Vaccine Prequalified by WHO - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006414\\\/en\\\/1625794\\\/21\\\/logo.jpg\",\"datePublished\":\"2022-11-04T03:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006414\\\/en\\\/1625794\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103006414\\\/en\\\/1625794\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sinovac-varicella-vaccine-prequalified-by-who\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SINOVAC Varicella Vaccine Prequalified by WHO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SINOVAC Varicella Vaccine Prequalified by WHO - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/","og_locale":"en_US","og_type":"article","og_title":"SINOVAC Varicella Vaccine Prequalified by WHO - Pharma Trend","og_description":"BEIJING&#8211;(BUSINESS WIRE)&#8211;Sinovac Biotech Ltd. (\u201cSINOVAC\u201d or the \u201cCompany\u201d) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization (WHO) for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-04T03:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SINOVAC Varicella Vaccine Prequalified by WHO","datePublished":"2022-11-04T03:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/"},"wordCount":534,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/","url":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/","name":"SINOVAC Varicella Vaccine Prequalified by WHO - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/21\/logo.jpg","datePublished":"2022-11-04T03:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221103006414\/en\/1625794\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sinovac-varicella-vaccine-prequalified-by-who\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SINOVAC Varicella Vaccine Prequalified by WHO"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50486"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50486\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}